Holen Sie sich die Stockscreener-App
21.47
1.13%
-0.25
Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten
Earnings call transcript: ACADIA Q1 2026 misses forecasts, stock steady By Investing.com - Investing.com Australia
Earnings call transcript: ACADIA Q1 2026 misses forecasts, stock steady - Investing.com UK
ACADIA Pharmaceuticals targets $1B brand opportunity as key neuropsychiatry data looms - MSN
ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms - sharewise.com
Acadia Pharmaceuticals (ACAD) lags Q1 earnings and revenue estimates - MSN
ACADIA Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - 富途牛牛
Earnings Miss: ACADIA Pharmaceuticals Inc. Missed EPS By 58% And Analysts Are Revising Their Forecasts - Yahoo Finance
(ACAD) Volatility Zones as Tactical Triggers - Stock Traders Daily
Acadia launches powder version of Rett syndrome treatment in the US - MSN
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Mixed Q1 2026 Results And EU Trofinetide Setback - simplywall.st
Acadia reaffirms 2026 total revenue guidance of $1.22B-$1.28B as remlifanserin Phase II ADP readout nears - MSN
Acadia Pharmaceuticals (ACAD) Margin Expansion To 34.3% Tests Bearish Growth Concerns - Sahm
What ACADIA Pharmaceuticals (ACAD)'s Earnings Miss, EU Setback and R&D Transition Means For Shareholders - Yahoo Finance
ACAD Maintained by Citigroup -- Price Target Lowered to $32 - GuruFocus
ACADIA Pharmaceuticals stock (US0042251084): Focus on CNS drug pipeline and commercial execution - AD HOC NEWS
ACAD Stock Price, Quote & Chart | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
ACADIA Pharmaceuticals Signals Confident Path After Q1 Call - TipRanks
ACADIA Pharmaceuticals Q1 2026 Earnings Call Highlights – DAYBUE and NUPLAZID UpdateNews and Statistics - IndexBox
ACADIA: Buy Rating Reiterated on Durable Commercial Strength and Pipeline Catalysts; $37 Price Target Maintained - TipRanks
H.C. Wainwright Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $37 - Moomoo
ACAD Q1 earnings & revenues miss estimates despite Y/Y sales growth - MSN
Earnings call transcript: ACADIA Pharmaceuticals misses Q1 2026 EPS forecast By Investing.com - Investing.com South Africa
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth - The Globe and Mail
Canaccord reiterates Acadia Pharmaceuticals stock rating on Q1 results By Investing.com - Investing.com South Africa
ACADIA Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Canaccord reiterates Acadia Pharmaceuticals stock rating on Q1 results - Investing.com UK
Acadia Pharmaceuticals Q1 2026 Financial Results: DAYBUE and NUPLAZID Sales Growth, Reaffirms Full Year Guidance - Minichart
Acadia (ACAD) Q1 2026 Earnings Transcript - AOL.com
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance - BioSpace
ACADIA Pharmaceuticals Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:ACAD) 2026-05-06 - Seeking Alpha
ACADIA (NASDAQ: ACAD) posts Q1 2026 sales gains but lower profit - Stock Titan
Earnings call transcript: ACADIA Pharmaceuticals misses Q1 2026 EPS forecast - Investing.com Nigeria
ACADIA Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
MSN Money - MSN
Acadia Pharmaceuticals (ACAD) Lags Q1 Earnings and Revenue Estimates - Yahoo Finance
Earnings Scheduled For May 6, 2026 - Benzinga
Acadia (NASDAQ: ACAD) reaffirms 2026 outlook after Q1 results - Stock Titan
Acadia Pharmaceuticals (NASDAQ:ACAD) Q1 2026 Earnings Miss Sends Stock Lower - ChartMill
ACADIA PHARMACEUTICALS ($ACAD) Releases Q1 2026 Earnings - Quiver Quantitative
Acadia: Q1 Earnings Snapshot - WKYC
Acadia posts $268M quarter as Alzheimer’s study nears fall data - Stock Titan
ACADIA Pharmaceuticals earnings up next: Can drug sales sustain momentum? By Investing.com - Investing.com South Africa
ACADIA Pharmaceuticals earnings up next: Can drug sales sustain momentum? - Investing.com Australia
R&D Leadership Transition and Trial Continuity Could Be A Game Changer For ACADIA Pharmaceuticals (ACAD) - Sahm
Acadia Pharmaceuticals CFO Mark Schneyer sells $76,395 in stock By Investing.com - Investing.com Canada
Acadia Pharmaceuticals officer Kihara sells $29,024 stock By Investing.com - Investing.com India
Acadia Pharmaceuticals CFO Mark Schneyer sells $76,395 in stock - Investing.com
Acadia Pharmaceuticals officer Kihara sells $29,024 stock - Investing.com
ACADIA PHARMACEUTICALS (NASDAQ: ACAD) officer sells shares for RSU tax withholding - Stock Titan
Acadia Pharmaceuticals (ACAD) CFO sells shares to cover RSU taxes - Stock Titan
0.48%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):